Opportunity Information: Apply for PAR 16 265
Apply for PAR 16 265
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Reducing the Duration of Untreated Psychosis in the United States (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242,.
- This funding opportunity was created on May 17, 2016 and posted on May 17, 2016.
- Applicants must submit their applications by Mar 19, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Reducing the Duration of Untreated Psychosis in the United States (R01) opportunity (PAR 16-265) is a National Institutes of Health research project grant focused on shortening the time between the onset of psychotic symptoms and the start of effective, evidence-based care for people experiencing a first episode of psychosis (FEP). The need is large and time-sensitive: roughly 100,000 adolescents and young adults in the United States experience FEP each year, and the early stage of psychotic illness is widely considered a critical window where the trajectory of schizophrenia-spectrum and related psychotic disorders may still be altered. The central problem the FOA targets is that, in the U.S., treatment commonly begins far too late, with many studies showing delays of one to three years between symptom onset and entry into specialized care. Because earlier treatment is associated with better short- and long-term outcomes, this gap represents a major, actionable weakness in the current system.
A key concept driving the announcement is the duration of untreated psychosis (DUP), which refers to the time from the emergence of psychotic symptoms to the initiation of appropriate treatment. The World Health Organization has advocated for reducing DUP to three months or less, underscoring just how urgent rapid identification and treatment are considered internationally. The FOA is built around the idea that DUP can be reduced by fixing real-world breakdowns in the pathway to care: delays in recognizing symptoms, uncertainty about where to refer, long waits, poor handoffs between services, and difficulties engaging young people and families once contact is made. Rather than simply documenting the problem, the goal is to rigorously test strategies that are practical and reproducible, meaning approaches that can be implemented in typical U.S. settings and scaled if they work.
The care model the announcement aims to connect people to more quickly is Coordinated Specialty Care (CSC), a team-based approach for early psychosis that integrates medication management, psychotherapy, family education and support, and rehabilitation services such as supported employment and education. Compared to more traditional, fragmented treatment, CSC has shown benefits across clinical and functional outcomes. However, the FOA emphasizes that even high-quality CSC is less effective if people arrive late; timing is a major determinant of outcomes. In other words, the opportunity is not primarily about inventing a brand-new treatment for psychosis, but about improving systems so that existing evidence-based early psychosis services reach people much sooner.
From a research standpoint, applicants are expected to design and test interventions that remove bottlenecks or close gaps that keep people from reaching CSC quickly. This could involve improving early identification of FEP in community settings, building faster and more reliable referral pathways, strengthening outreach and engagement methods that reduce drop-off before treatment begins, or addressing logistical and administrative barriers that create delays. The emphasis on "practical, reproducible strategies" signals that the NIH is looking for approaches that can realistically be adopted by health systems, schools, community providers, and other front-line points of contact, and that can be replicated across regions rather than being dependent on a single highly resourced site.
Administratively, this is a discretionary NIH grant using the R01 mechanism, categorized under health (CFDA 93.242). Eligibility is broad and includes many types of U.S. organizations that can conduct research, such as state, county, and local governments; public and private institutions of higher education; tribal governments and tribal organizations; nonprofits (including 501(c)(3) and non-501(c)(3)); public housing authorities/Indian housing authorities; for-profit organizations (other than small businesses) and small businesses, with a note to consult the FOA for any additional eligibility clarifications. The sponsoring agency is listed as HHS-NIH, and the posting dates indicate it was created and posted May 17, 2016, with a closing date of March 19, 2019. Overall, the opportunity is aimed at generating actionable evidence on how to substantially reduce DUP in the U.S. by making it easier and faster for young people experiencing early psychosis to be identified, referred, and successfully engaged in CSC before functional decline becomes entrenched.
FAQs: Reducing the Duration of Untreated Psychosis in the United States (R01) (PAR 16-265)
What is this funding opportunity?
This opportunity is an NIH research project grant (R01) focused on reducing the Duration of Untreated Psychosis (DUP) in the United States by improving how quickly people experiencing a first episode of psychosis (FEP) reach effective, evidence-based care.
What problem is the FOA trying to solve?
The FOA targets long delays between the onset of psychotic symptoms and entry into specialized care. Many studies show treatment often begins one to three years after symptoms start, which is considered far too late given the importance of early intervention.
What is DUP (Duration of Untreated Psychosis)?
DUP refers to the time from the emergence of psychotic symptoms to the initiation of appropriate treatment. The FOA is centered on reducing this time by addressing real-world breakdowns in the pathway to care.
Why is reducing DUP considered urgent?
The early stage of psychotic illness is widely viewed as a critical window during which the long-term trajectory of schizophrenia-spectrum and related psychotic disorders may still be altered. Earlier treatment is associated with better short- and long-term outcomes, so reducing delays is time-sensitive and potentially high-impact.
How common is first episode psychosis (FEP) in the United States?
The opportunity notes that roughly 100,000 adolescents and young adults in the United States experience FEP each year.
Is this FOA about developing a new treatment for psychosis?
Not primarily. The emphasis is on improving systems so that existing evidence-based early psychosis services reach people much sooner, rather than inventing an entirely new treatment approach.
What type of care is the FOA trying to connect people to more quickly?
The FOA is aimed at getting people to Coordinated Specialty Care (CSC) faster. CSC is a team-based early psychosis care model that integrates multiple services into a coordinated approach.
What is Coordinated Specialty Care (CSC)?
CSC is a team-based approach for early psychosis that integrates medication management, psychotherapy, family education and support, and rehabilitation services such as supported employment and education.
Why does the FOA emphasize speed even if CSC is high quality?
The FOA highlights that even high-quality CSC is less effective if people arrive late. Timing is described as a major determinant of outcomes, which is why reducing DUP is central.
What kinds of barriers contribute to long DUP in the U.S.?
The FOA points to real-world breakdowns such as delays in recognizing symptoms, uncertainty about where to refer, long waits, poor handoffs between services, and difficulties engaging young people and families once contact is made.
What types of research strategies is NIH looking to fund under this opportunity?
Applicants are expected to design and test interventions that remove bottlenecks or close gaps that prevent people from reaching CSC quickly. The FOA stresses strategies that are practical and reproducible in typical U.S. settings and scalable if effective.
What are examples of intervention areas mentioned in the FOA description?
The FOA description highlights areas such as improving early identification of FEP in community settings, building faster and more reliable referral pathways, strengthening outreach and engagement methods to reduce drop-off before treatment begins, and addressing logistical and administrative barriers that create delays.
What does it mean that strategies should be "practical and reproducible"?
It means the approaches should be realistic for typical U.S. settings (not dependent on a single highly resourced site), capable of being implemented by real-world systems (such as health systems and community providers), and replicable across regions.
Which settings does the FOA imply could be part of improved pathways to care?
The FOA description references adoption by health systems, schools, community providers, and other front-line points of contact involved in identifying, referring, and engaging people early.
What funding mechanism is used?
This is a discretionary NIH grant using the R01 mechanism (research project grant).
Which agency is sponsoring the opportunity?
The sponsoring agency is listed as HHS-NIH (National Institutes of Health within the U.S. Department of Health and Human Services).
What is the CFDA number and category noted?
The opportunity is categorized under health and lists CFDA 93.242.
Who is eligible to apply?
Eligibility is described as broad and includes many types of U.S. organizations able to conduct research, including state, county, and local governments; public and private institutions of higher education; tribal governments and tribal organizations; nonprofits (501(c)(3) and non-501(c)(3)); public housing authorities/Indian housing authorities; for-profit organizations (other than small businesses); and small businesses. The FOA notes applicants should consult the full announcement for any additional eligibility clarifications.
Is eligibility limited to nonprofit organizations?
No. The eligibility list includes nonprofit organizations as well as government entities, higher education institutions, tribal organizations, for-profit organizations (other than small businesses), and small businesses.
What is the time frame for this opportunity (posting and closing dates)?
The opportunity was created and posted on May 17, 2016, and lists a closing date of March 19, 2019.
What is the overall goal of the research funded through this FOA?
The goal is to generate actionable evidence on how to substantially reduce DUP in the United States by making it easier and faster for adolescents and young adults experiencing early psychosis to be identified, referred, and successfully engaged in CSC before functional decline becomes entrenched.
Does the FOA reference any benchmark or external target for DUP reduction?
Yes. The description notes that the World Health Organization has advocated for reducing DUP to three months or less, reflecting the urgency placed on rapid identification and treatment internationally.
Browse more opportunities from the same category: Health
Next opportunity: Reducing the Duration of Untreated Psychosis in the United States (R34)
Previous opportunity: Request for Information - Enabling Technologies for Ultra-Safe and Secure Modular Nuclear Energy Systems
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 265
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 265) also looked into and applied for these:
| Funding Opportunity |
|---|
| Reducing the Duration of Untreated Psychosis in the United States (R34) Apply for PAR 16 264 Funding Number: PAR 16 264 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
| Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01) Apply for PAR 16 262 Funding Number: PAR 16 262 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities Outside the United States Apply for CDC RFA IP16 1603 Funding Number: CDC RFA IP16 1603 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $400,000 |
| NHLBI Career Transition Award for Intramural Fellows (K22) Apply for PAR 16 267 Funding Number: PAR 16 267 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization Apply for CDC RFA IP16 1606 Funding Number: CDC RFA IP16 1606 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $2,000,000 |
| Introducing or Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs Outside of the United States Apply for CDC RFA IP16 1604 Funding Number: CDC RFA IP16 1604 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $250,000 |
| NIAID Clinical Trial Implementation Grant (R01) Apply for PAR 16 269 Funding Number: PAR 16 269 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01) Apply for RFA AI 16 047 Funding Number: RFA AI 16 047 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03) Apply for PAR 16 268 Funding Number: PAR 16 268 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 16 270 Funding Number: PAR 16 270 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 16 272 Funding Number: PAR 16 272 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) Apply for PAR 16 271 Funding Number: PAR 16 271 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 17 008 Funding Number: HRSA 17 008 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS) Apply for CDC RFA PS14 140204CONT17 Funding Number: CDC RFA PS14 140204CONT17 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| CDC’s National Undergraduate Student Program: A Public Health Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110106CONT16 Funding Number: CDC RFA MN11 110106CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Fogarty Global Health Training Program (D43) Apply for RFA TW 16 002 Funding Number: RFA TW 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: $1,100,000 |
| Surveillance, intervention, and referral to services activities for infants with microcephaly or other adverse outcomes linked with the Zika virus Apply for CDC RFA DD16 1605 Funding Number: CDC RFA DD16 1605 Agency: HHS-CDC-NCBDDD Category: Health Funding Amount: $360,000 |
| Developing New Clinical Decision Support to Disseminate and Implement Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 282 Funding Number: PA 16 282 Agency: HHS-AHRQ Category: Health Funding Amount: $750,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Specialized Center Cooperative Agreements (U54) Apply for RFA OD 16 011 Funding Number: RFA OD 16 011 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Comprehensive Platform for Integrated Communication Initiative (CPICI) Apply for RFA 621 16 000003 Funding Number: RFA 621 16 000003 Agency: USAID-TAN Category: Health Funding Amount: $46,200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 265", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.